Feng Wang

Professor and Director of Medical Oncology dept from Sun Yat-sen University Cancer Center. UT MD Anderson alumni

[Cancer Cell @Cancer_Cell]

Online Now: Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer https://t.co/r0bGnjJRwq

[Feng Wang @FengWan25720657]

@Annals_Oncology @YanceyChen_lol Final analysis of Jupiter-06 study showed the EGIC
model is effective in predicting the long term survival. Potential combination strategies are provided.

[Annals of Oncology @Annals_Oncology]

🆕article in press: Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma @FengWan25720657 @YanceyChen_lol https://t.co/Nn9PLWzSdP

[Cancer Cell @Cancer_Cell]

Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer https://t.co/FfdISNwpb5

[Feng Wang @FengWan25720657]

We updated the long term survival data of Neosummit-01 trial. Always happy to meet friends. #ASCOGI26 #gastriccancer

[Signal Transduction and Targeted Therapy (STTT) @sigtrans_sttt]

#Garsorasib, alone or with #Cetuximab, shows strong efficacy, manageable safety, and a favorable response in heavily pretreated #KRASG12C-mutated metastatic #ColorectalCancer, supporting improved precision therapy outcomes. @FengWan25720657

#STTT: https://t.co/UFlU1XGErF

[Feng Wang @FengWan25720657]

Combo IO works better than single drug in the neoadjuvant setting in MSIH colorectal cancer. @Cancer_Cell

[Cancer Cell @Cancer_Cell]

Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study https://t.co/yycvePP854

[Feng Wang @FengWan25720657]

During the days I was in Lanzhou, Gansu, I walked along Yellow River everyday and was amazed by its magnificent view.

[Feng Wang @FengWan25720657]

“The striking cover image showcases the dramatic meeting of the Tao River and the Yellow River in Gansu Province, China, where two distinct currents join to form a powerful, unified flow. This visual spectacle mirrors the findings of the Neoshot 1b study by Wang et al.,

[Cancer Cell @Cancer_Cell]

Dive into our October issue, out now, and keep up with our current content: https://t.co/1sejtFyxmo

[Feng Wang @FengWan25720657]

Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors https://t.co/jZRvss6UKE

[Signal Transduction and Targeted Therapy (STTT) @sigtrans_sttt]

Phase II trial shows #KRASG12CInhibitor #Garsorasib, alone or with #cetuximab, delivers promising efficacy and manageable safety in heavily pretreated KRAS G12C–mutated #ColorectalCancer patients. @FengWan25720657

#STTT #OpenAccess: https://t.co/UFlU1XGErF

[Feng Wang @FengWan25720657]

Our preview of two very interesting papers. One from Dr Bardelli's lab, the other from Dr Diaz's group.
@BardelliLab
@ldiaz1971 @Cancer_Cell

[Cancer Cell @Cancer_Cell]

Online Now: Drug-induced mismatch repair deficiency: Mixed prospects https://t.co/PPYeRoIPBd

[Feng Wang @FengWan25720657]

It's always great to meet old friends and make new friends in ASCO.

[Nature Medicine @NatureMedicine]

Now at #ASCO24: In the phase 3 FRUTIGA trial, the multi anti-VEGFR inhibitor #fruquintinib + chemotherapy significantly extended progression-free survival, but not overall survival, as 2L therapy in patients with advanced #GastricCancer or #GEJCancer https://t.co/i64ljYnQ4N

[Feng Wang @FengWan25720657]

Having fun at ASCO and meeting old friends. #ASCO24

[Feng Wang @FengWan25720657]

Thanks to Cell for inviting us to write this commentary. Challenges and opportunities in oncology drug development and clinical research in China: Cell https://t.co/rt2UIl6cIc @CellCellPress

[Feng Wang @FengWan25720657]

@YiHsinLiang1 Thank you, Yi-Hsin.

[Nature Medicine @NatureMedicine]

In a phase 2 trial comparing anti-PD-1 + anti-VEGF + HDAC inhibitor vs. anti-PD-1 + HDAC inhibitor in patients with MSS/pMMR #ColorectalCancer, the triplet combo leads to better 18 week progression-free survival. #ColorectalCancerAwarenessMonth
https://t.co/KzLX7HX75k

[Feng Wang @FengWan25720657]

The Capability-01 trial was just published. The combination of HADCi, anti-PD-1 and anti-VEGF achieved an ORR of 44% with a mPFS 7.3 mos in MSS mCRC patients. Thanks to the study team, all patients and family. #colorectalcancer #Immunology #Cancer @NatureMedicine

[Shi-Shaun Wong (王诗翔) @WangShxiang]

Excited to share my recent work published in Nature Communications with the title "Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer." https://t.co/u1LtQdAy4t #MachineLearning #CancerGenomics 📚🔬